Erasca, Inc. Announces 2024 Annual Meeting of Stockholders on June 20
Ticker: ERAS · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1761918
Sentiment: neutral
Topics: Erasca, Annual Meeting, Proxy Statement, Virtual Meeting, Stockholder Voting
TL;DR
Erasca, Inc. will host its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, encouraging online voting and proxy submission.
AI Summary
Erasca, Inc. (ERAS) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Erasca, Inc. will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, at 11:30 a.m. Pacific Time. The meeting will be conducted as a completely virtual meeting via live webcast. Stockholders can access and review proxy materials on the Internet instead of receiving printed copies. The company is providing access to documents online to lower delivery costs and reduce environmental impact. Voting can be done by phone, via the Internet, or by returning a proxy card if paper copies were received.
Why It Matters
For investors and stakeholders tracking Erasca, Inc., this filing contains several important signals. The virtual format and internet-based proxy material delivery aim to reduce costs and environmental impact for the company and its stockholders. Encouraging prompt voting via multiple channels ensures stockholder representation and participation in key corporate decisions at the Annual Meeting.
Risk Assessment
Risk Level: low — Erasca, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.
Analyst Insight
Stockholders should review the proxy materials and vote their shares for the upcoming Annual Meeting on June 20, 2024.
Key Numbers
- June 20, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 11:30 a.m. Pacific Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
Key Players & Entities
- Erasca, Inc. (company) — Registrant and filer of the proxy statement
- June 20, 2024 (date) — Date of the Annual Meeting of Stockholders
- April 26, 2024 (date) — Date of the filing and the letter to stockholders
- San Diego, CA (location) — Location of Erasca, Inc. headquarters
FAQ
When did Erasca, Inc. file this DEF 14A?
Erasca, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Erasca, Inc. (ERAS).
Where can I read the original DEF 14A filing from Erasca, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Erasca, Inc..
What are the key takeaways from Erasca, Inc.'s DEF 14A?
Erasca, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: Erasca, Inc. will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, at 11:30 a.m. Pacific Time.. The meeting will be conducted as a completely virtual meeting via live webcast.. Stockholders can access and review proxy materials on the Internet instead of receiving printed copies..
Is Erasca, Inc. a risky investment based on this filing?
Based on this DEF 14A, Erasca, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.
What should investors do after reading Erasca, Inc.'s DEF 14A?
Stockholders should review the proxy materials and vote their shares for the upcoming Annual Meeting on June 20, 2024. The overall sentiment from this filing is neutral.
How does Erasca, Inc. compare to its industry peers?
Erasca, Inc. operates in the pharmaceutical preparations industry, focusing on developing therapies for cancer.
Are there regulatory concerns for Erasca, Inc.?
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, governing proxy solicitations.
Industry Context
Erasca, Inc. operates in the pharmaceutical preparations industry, focusing on developing therapies for cancer.
Regulatory Implications
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the proxy statement for details on proposals and voting procedures.
- Vote your shares by phone, internet, or mail by the deadline.
- Attend the virtual Annual Meeting on June 20, 2024, if interested.
Key Dates
- 2024-06-20: Annual Meeting of Stockholders — Key date for stockholder voting and participation in corporate governance.
- 2024-04-26: Filing Date — Date the definitive proxy statement was filed with the SEC.
Year-Over-Year Comparison
This is the initial definitive proxy statement for the 2024 Annual Meeting, following the company's standard annual reporting cycle.
Filing Stats: 4,959 words · 20 min read · ~17 pages · Grade level 11.8 · Accepted 2024-04-26 16:06:02
Key Financial Figures
- $0.0001 — f record of shares of our common stock, $0.0001 par value per share, as of the close of
Filing Documents
- d697760ddef14a.htm (DEF 14A) — 383KB
- g697760dsp36.jpg (GRAPHIC) — 128KB
- g697760dsp36a.jpg (GRAPHIC) — 4KB
- g697760dsp36b.jpg (GRAPHIC) — 3KB
- g697760dsp36d.jpg (GRAPHIC) — 3KB
- g697760dsp37.jpg (GRAPHIC) — 16KB
- g697760dsp37a.jpg (GRAPHIC) — 1KB
- g697760g10g00.jpg (GRAPHIC) — 37KB
- g697760g88z25.jpg (GRAPHIC) — 37KB
- 0001193125-24-117977.txt ( ) — 694KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 33 2025 STOCKHOLDER PROPOSALS 35 ERASCAS ANNUAL REPORT ON FORM 10-K 36 Table of Contents PROXY STATEMENT ERASCA, INC. 3115 Merryfield Row, Suite 300, San Diego, California 92121 General This proxy statement is furnished in connection with the solicitation by the board of directors (the Board) of Erasca, Inc. of proxies to be voted at our Annual Meeting of Stockholders to be held virtually on Thursday, June 20, 2024 (the Annual Meeting), at 11:30 a.m., Pacific Time, and at any continuation, postponement or adjournment thereof. Holders of record of shares of our common stock, $0.0001 par value per share, as of the close of business on April 24, 2024 (the Record Date), will be entitled to notice of and to vote at the Annual Meeting and any continuation, postponement or adjournment thereof. As of the Record Date, there were 173,358,966 shares of our common stock outstanding and entitled to vote at the Annual Meeting. Each share of common stock is entitled to one vote on any matter presented to stockholders at the Annual Meeting. This proxy statement and the Companys Annual Report to Stockholders for the year ended December 31, 2023 (the 2023 Annual Report), or Notice of Internet Availability of Proxy Materials, as applicable, will be sent on or about May 7, 2024 to our stockholders on the Record Date. In this proxy IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON THURSDAY, JUNE 20, 2024: This Proxy Statement and our 2023 Annual Report to Stockholders are available at: www.proxydocs.com/ERAS. Proposals At the Annual Meeting, our stockholders will be asked: 1. To elect Jean I. Liu, J.D. and Pratik S. Multani, M.D. as Class III directors for a three-year term that expires at the 2027 Annual